FDA Faults Cytogam Sales Literature For Unsubstantiated Long-Term Survival Claim
This article was originally published in The Pink Sheet Daily
Executive Summary
Clinical trial's long-term survival was not statistically significant, agency says in letter to CLS Behring.
You may also be interested in...
CytoGam Acquisition Strengthens ZLB Behring's Immunoglobulin Portfolio
MedImmune divests the transplantation treatment to ZLB Behring for an up-front payment of $50 mil.
Rx Misbranding Penalties Should Be Stronger To Stop Counterfeiting, FDA Says
Industry also seems supportive of the idea, while Pew touts the power of the power of track-and-trace as a deterrent.
Track-And-Trace: With Deadline a Year Away, Some Lessons from Early Adopters
EMD Serono has been tracking Serostim packages since 2002; J&J is using Prezista 600 mg as a trial run for serialization.